Compare CBAN & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | CCCC |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 240.3M |
| IPO Year | 1998 | 2020 |
| Metric | CBAN | CCCC |
|---|---|---|
| Price | $17.40 | $2.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 62.2K | ★ 1.7M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 26.78 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $122,550,000.00 | $30,108,000.00 |
| Revenue This Year | $20.97 | N/A |
| Revenue Next Year | $25.65 | N/A |
| P/E Ratio | $10.99 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $13.99 | $1.09 |
| 52 Week High | $18.41 | $5.10 |
| Indicator | CBAN | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 51.47 |
| Support Level | $17.00 | $2.41 |
| Resistance Level | $17.70 | $2.84 |
| Average True Range (ATR) | 0.36 | 0.19 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 82.25 | 49.99 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.